Back to top
Top
U.S. flag

An official website of the United States government

Dot gov

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Https

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

DERep Home Page

["Patient Characteristic, Race": "Race"]

Performance/Reporting Period
2024
Value Set Description from VSAC
Clinical Focus: n/a Data Element Scope: n/a Inclusion Criteria: n/a Exclusion Criteria: n/a

Constrained to codes in the Race value set (2.16.840.1.114222.4.11.836)

QDM Datatype and Definition

"Patient Characteristic, Race"

Data elements that meet criteria using this datatype should document the patient’s race.

Timing: Race does not have a specific timing. Measures using "Patient Characteristic, Race" should address the most recent entry in the clinical record.

eCQMs using this data element:
CMS1028v2 - Severe Obstetric Complications
CMS104v12 - Discharged on Antithrombotic Therapy
CMS108v12 - Venous Thromboembolism Prophylaxis
CMS117v12 - Childhood Immunization Status
CMS1188v1 - Sexually Transmitted Infection (STI) Testing for People with HIV
CMS122v12 - Diabetes: Hemoglobin A1c (HbA1c) Poor Control (> 9%)
CMS124v12 - Cervical Cancer Screening
CMS125v12 - Breast Cancer Screening
CMS128v12 - Anti-depressant Medication Management
CMS129v13 - Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer Patients
CMS130v12 - Colorectal Cancer Screening
CMS131v12 - Diabetes: Eye Exam
CMS133v12 - Cataracts: 20 over 40 or Better Visual Acuity within 90 Days Following Cataract Surgery
CMS135v12 - Heart Failure (HF): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) or Angiotensin Receptor-Neprilysin Inhibitor (ARNI) Therapy for Left Ventricular Systolic Dysfunction (LVSD)
CMS136v13 - Follow-Up Care for Children Prescribed ADHD Medication (ADD)
CMS137v12 - Initiation and Engagement of Substance Use Disorder Treatment
CMS138v12 - Preventive Care and Screening: Tobacco Use: Screening and Cessation Intervention
CMS139v12 - Falls: Screening for Future Fall Risk
CMS142v12 - Diabetic Retinopathy: Communication with the Physician Managing Ongoing Diabetes Care
CMS143v12 - Primary Open-Angle Glaucoma (POAG): Optic Nerve Evaluation
CMS144v12 - Heart Failure (HF): Beta-Blocker Therapy for Left Ventricular Systolic Dysfunction (LVSD)
CMS145v12 - Coronary Artery Disease (CAD): Beta-Blocker Therapy-Prior Myocardial Infarction (MI) or Left Ventricular Systolic Dysfunction (LVEF) less than or equal to 40%
CMS146v12 - Appropriate Testing for Pharyngitis
CMS149v12 - Dementia: Cognitive Assessment
CMS153v12 - Chlamydia Screening in Women
CMS154v12 - Appropriate Treatment for Upper Respiratory Infection (URI)
CMS155v12 - Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents
CMS156v12 - Use of High-Risk Medications in Older Adults
CMS157v12 - Oncology: Medical and Radiation - Pain Intensity Quantified
CMS159v12 - Depression Remission at Twelve Months
CMS165v12 - Controlling High Blood Pressure
CMS177v12 - Child and Adolescent Major Depressive Disorder (MDD): Suicide Risk Assessment
CMS190v12 - Intensive Care Unit Venous Thromboembolism Prophylaxis
CMS22v12 - Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up Documented
CMS249v6 - Appropriate Use of DXA Scans in Women Under 65 Years Who Do Not Meet the Risk Factor Profile for Osteoporotic Fracture
CMS2v13 - Preventive Care and Screening: Screening for Depression and Follow-Up Plan
CMS314v1 - HIV Viral Suppression
CMS334v5 - Cesarean Birth
CMS347v7 - Statin Therapy for the Prevention and Treatment of Cardiovascular Disease
CMS349v6 - HIV Screening
CMS506v6 - Safe Use of Opioids - Concurrent Prescribing
CMS50v12 - Closing the Referral Loop: Receipt of Specialist Report
CMS529v4 - Core Clinical Data Elements for the Hybrid Hospital-Wide Readmission (HWR) Measure with Claims and Electronic Health Record Data
CMS56v12 - Functional Status Assessment for Total Hip Replacement
CMS645v7 - Bone density evaluation for patients with prostate cancer and receiving androgen deprivation therapy
CMS646v4 - Intravesical Bacillus-Calmette-Guerin for non-muscle invasive bladder cancer
CMS68v13 - Documentation of Current Medications in the Medical Record
CMS69v12 - Preventive Care and Screening: Body Mass Index (BMI) Screening and Follow-Up Plan
CMS71v13 - Anticoagulation Therapy for Atrial Fibrillation or Flutter
CMS72v12 - Antithrombotic Therapy By End of Hospital Day 2
CMS74v13 - Primary Caries Prevention Intervention as Offered by Dentists
CMS75v12 - Children Who Have Dental Decay or Cavities
CMS771v5 - Urinary Symptom Score Change 6-12 Months After Diagnosis of Benign Prostatic Hyperplasia
CMS816v3 - Hospital Harm - Severe Hypoglycemia
CMS819v2 - Hospital Harm - Opioid-Related Adverse Events
CMS844v4 - Core Clinical Data Elements for the Hybrid Hospital-Wide (All-Condition, All-Procedure) Risk-Standardized Mortality Measure (HWM)
CMS871v3 - Hospital Harm - Severe Hyperglycemia
CMS90v13 - Functional Status Assessments for Heart Failure
CMS951v2 - Kidney Health Evaluation
CMS986v2 - Global Malnutrition Composite Score
CMS996v4 - Appropriate Treatment for ST-Segment Elevation Myocardial Infarction (STEMI) Patients in the Emergency Department (ED)
Last Updated: Jun 29, 2023

We want your feedback

Feedback pertains to:
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.